[MO1] Mini-Oral Session 1　Lung Cancer / Thoracic Cancer 1（Cytotoxic）
【E】

[MO1-2] A phase II/III study comparing CBDCA + IRI with CBDCA + ETP for elderly patients with ED-SCLC (JCOG1201/TORG1528)

^○Hiroshi Tanaka¹, Tsuneo Shimokawa², Yuki Misumi², Hiroaki Okamoto², Isamu Okamoto³, Yukio Hosomi⁴, Shinji Atagi⁵, Toyoaki Hida⁶, Koichi Goto⁷, Hiroaki Akamatsu⁸, Masahiko Ando⁹, Ryunosuke Machida¹⁰, Junko Eba¹⁰, Tomoko Kataoka¹⁰, Yuichiro Ohe¹¹ (1.Department of Internal Medicine, Niigata Cancer Center Hospital, 2.Department of Respiratory Medicine, Yokohama Municipal Citizen’s Hospital, 3.Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 4.Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 5.Department of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, 6.Department of Thoracic Oncology, Aichi Cancer Center Hospital, 7.Department of Thoracic Oncology, National Cancer Center Hospital East, 8.Internal Medicine III, Wakayama Medical University, 9.Center for Advanced Medicine and Clinical Research, Nagoya University Hospital,, 10.Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, 11.Department of Thoracic Oncology, National Cancer Center Hospital,)